Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Real world data immuuncheckpointremmers vergelijkbaar met klinische studies
feb 2020 | Dermato-oncologie, Immuuntherapie